KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) Invested Capital (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Invested Capital for 15 consecutive years, with $114.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Invested Capital fell 10.12% year-over-year to $114.8 million, compared with a TTM value of $114.8 million through Dec 2025, down 10.12%, and an annual FY2025 reading of $114.8 million, down 10.12% over the prior year.
  • Invested Capital was $114.8 million for Q4 2025 at Travere Therapeutics, up from $73.6 million in the prior quarter.
  • Across five years, Invested Capital topped out at $362.7 million in Q1 2021 and bottomed at $15.1 million in Q2 2024.
  • Average Invested Capital over 5 years is $164.8 million, with a median of $125.6 million recorded in 2023.
  • The sharpest move saw Invested Capital tumbled 87.72% in 2024, then skyrocketed 570.66% in 2025.
  • Year by year, Invested Capital stood at $309.5 million in 2021, then plummeted by 83.89% to $49.9 million in 2022, then soared by 302.82% to $200.8 million in 2023, then crashed by 36.38% to $127.8 million in 2024, then dropped by 10.12% to $114.8 million in 2025.
  • Business Quant data shows Invested Capital for TVTX at $114.8 million in Q4 2025, $73.6 million in Q3 2025, and $101.6 million in Q2 2025.